0JDM.LSE IQVIA Holdings Inc.
- Market cap
- -
- P/E
- 46.0x
- P/B
- -
- ROE
- 17.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0JDM.LSE undervalued?
Graham numberThe Graham number of IQVIA Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IQVIA Holdings Inc. fundamental analysis
No fundamental analysis for IQVIA Holdings Inc. yet.
IQVIA Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services;…
Full company profileIQVIA Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IQVIA Holdings Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.90B | 9.71B | 10.4B | 11.1B | 11.4B | 13.9B | 14.4B | 15.0B | 15.4B | 16.3B | 17.3B |
| Gross Profit | 1.86B | 2.40B | 2.53B | 2.59B | 2.57B | 3.38B | 3.91B | 5.24B | 4.26B | 4.29B | 4.53B |
| Operating Income | 847M | 775M | 810M | 857M | 782M | 1.42B | 1.84B | 1.98B | 2.27B | 2.29B | 2.33B |
| EBITDA | 1.01B | 1.66B | 1.88B | 1.88B | 2.06B | 2.75B | 2.89B | 3.20B | 3.49B | 3.46B | 3.53B |
| Net Income | 115M | 1.28B | 259M | 191M | 279M | 966M | 1.09B | 1.36B | 1.37B | 1.36B | 1.17B |
| EPS | 0.76 | 5.74 | 1.24 | 0.96 | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 | 7.84 | 7.03 |
| Balance Sheet | |||||||||||
| Total Assets | 21.2B | 22.9B | 22.5B | 23.3B | 24.6B | 24.7B | 25.3B | 26.7B | 26.9B | 29.9B | 30.5B |
| Total Liabilities | 12.3B | 14.6B | 15.6B | 17.0B | 18.3B | 18.6B | 19.6B | 20.6B | 20.8B | 23.3B | 23.7B |
| Shareholders' Equity | 8.63B | 8.00B | 6.71B | 6.00B | 6.00B | 6.04B | 5.77B | 6.11B | 6.07B | 6.50B | 6.66B |
| Cash & Short-term Investments | 1.24B | 1.01B | 938M | 899M | 1.90B | 1.48B | 1.31B | 1.50B | 1.84B | 2.14B | 2.42B |
| Total Debt | 7.20B | 10.2B | 11.0B | 12.2B | 13.0B | 12.8B | 13.4B | 14.3B | 14.5B | 16.2B | 16.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 860M | 970M | 1.25B | 1.42B | 1.96B | 2.94B | 2.26B | 2.15B | 2.72B | 2.65B | 2.67B |
| Capital Expenditure | 164M | 369M | 459M | 582M | 616M | 640M | 674M | 649M | 602M | 603M | 644M |
| Free Cash Flow | 696M | 601M | 795M | 835M | 1.34B | 2.30B | 1.59B | 1.50B | 2.11B | 2.05B | 2.02B |
| Ratios | |||||||||||
| ROE | 1.3% | 16.0% | 3.9% | 3.2% | 4.6% | 16.0% | 18.9% | 22.2% | 22.6% | 20.9% | 17.6% |
| ROA | 0.5% | 5.6% | 1.1% | 0.8% | 1.1% | 3.9% | 4.3% | 5.1% | 5.1% | 4.5% | 3.9% |
| Net Profit Margin | 1.7% | 13.2% | 2.5% | 1.7% | 2.5% | 7.0% | 7.6% | 9.1% | 8.9% | 8.3% | 6.8% |
| Debt to Equity | 0.83x | 1.28x | 1.64x | 2.03x | 2.16x | 2.11x | 2.32x | 2.34x | 2.39x | 2.49x | 2.45x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IQVIA Holdings Inc. dividends
IQVIA Holdings Inc. has not paid dividends in the last 9 fiscal years.
Who owns IQVIA Holdings Inc.
- Insiders 1.09%
- Institutions 98.92%
- Public & others 0.00%
- Free float 156M
IQVIA Holdings Inc. company profile
- Company name
- IQVIA Holdings Inc.
- Ticker
- 0JDM.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 95,000
- Fiscal year end
- December
- Address
- 2400 Ellis Road, Durham, NC, United States, 27703
- Phone
- 919 998 2000
- Website
- iqvia.com
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
IQVIA Holdings Inc. management
10- Mr. Ari BousbibCEO & Chairman · born 1961
- Mr. Eric M. Sherbet J.D.Executive VP, General Counsel & Secretary · born 1964
- Mr. W. Richard Staub IIIPresident of Research & Development Solutions · born 1963
- Mr. Alistair GrenfellPresident of Commercial Solutions · born 1974
- Mr. Michael J. Fedock MBAExecutive VP & Chief Financial Officer · born 1976
- Mr. James G. BerkshireExecutive Vice President of Global Infrastructure & Operations · born 1974
- Ms. Keriann CherofskySenior VP, Corporate Controller & Chief Accounting Officer · born 1985
- Dr. Jeffrey A. Spaeder M.D.Chief Medical & Scientific Officer
- Kerri JosephSenior Vice President of Investor Relations
- Mr. Duane SachsSenior Vice President of Corporate Development